-
-
-
-
-
-
-
Leerink Partners on Ultragenyx Pharma (RARE): FDA BLA acceptance positions co for two approvals, $150M oppty
-
-
-
-
-
-
-
Ultragenyx resubmits gene therapy application for rare brain disease
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A
-
-
-
-
-
-
-
Goldman Sachs on Ultragenyx Pharma (RARE): 'we remain constructive'
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE), Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita for TIO
-
-
-
-
-
-
-
Ultragenyx Reports Preliminary 2019 Revenue and Provides 2020 Crysvita Revenue Guidance
-
-
-
-
-
-
-
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorization in Europe for the Treatment of X–Linked Hypophosphatemia in Children
-
15,747 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

